Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX–Bevacizumab Drug Treatment Regimen

Limagne, Emeric; Euvrard, Romain; Thibaudin, Marion; Rébé, Cédric; Dérangère, Valentin; Chevriaux, Angélique; Boidot, Romain; Végran, Frédérique; Bonnefoy, Nathalie; Vincent, Julie; Bengrine-Lefèvre, Leïla; Ladoire, Sylvain; Delmas, Dominique; Apétoh, Lionel; Ghiringhelli, François

doi:10.1158/0008-5472.can-15-3164

Public

Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX–Bevacizumab Drug Treatment Regimen

Published in Cancer Research • Aug 5, 2016

Authors:

Emeric Limagne

Romain Euvrard

Marion Thibaudin

Abstract

Host immunity controls the development of colorectal cancer, and chemotherapy used to treat colorectal cancer is likely to recruit the host immune system at some level. Athough preclinical studies have argued that colorectal cancer drugs, such as 5-fluorouracil (5-FU) and oxaliplatin, exert such eff...

Subject

FOLFOX

Oxaliplatin

Medicine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!